Investing.com -- Danish drugmaker Novo Nordisk (NYSE: NVO ) plans to launch its weight-loss drug Wegovy in India with no anticipated supply constraints, the company announced Tuesday.

"We are committed to addressing the unmet needs of patients living with chronic diseases such as obesity, thus this will be a full launch," a Novo Nordisk spokesperson said in an emailed statement.

The company expressed confidence in maintaining a stable supply of the product in the Indian market, stating: "We do not anticipate any supply constraints and are confident of stable supply of the product in India."

Wegovy is Novo Nordisk’s popular medication for treating obesity, which has seen high demand in various markets globally.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.